July 26 (Reuters) - Oncolytics Biotech Inc
* Oncolytics biotech® to present reolysin® safety data in combination with chemotherapy at esmo 2017 congress
* Oncolytics biotech inc - has been granted an end-of-phase 2 meeting with united states food and drug administration (fda), taking place in august 2017.
* Oncolytics biotech inc - company expects to announce outcome of meeting with fda in q4 of 2017. Source text for Eikon: Further company coverage: